Startseite › Myelodysplastische Syndrome › Washington › Seattle
Klinische Studien zu Myelodysplastische Syndrome in Seattle, WA
21 Studien zu Myelodysplastische Syndrome suchen Teilnehmer an Standorten in und um Seattle (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Teilnehmer gesuchtPhase 2
- Swedish Medical Center-First Hill, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Teilnehmer gesuchtPhase 1
- Fred Hutchinson Cancer Center, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Teilnehmer gesuchtPhase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Teilnehmer gesuchtPhase 1/2
- University of Washington, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Teilnehmer gesuchtPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Teilnehmer gesuchtPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
Teilnehmer gesuchtBeobachtungsstudie
- Fred Hutchinson, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Teilnehmer gesuchtPhase 1/2
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Teilnehmer gesuchtPhase 2
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Teilnehmer gesuchtPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Teilnehmer gesuchtPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Teilnehmer gesuchtPhase 2Gesunde Freiwillige willkommen
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Teilnehmer gesuchtPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Teilnehmer gesuchtPhase 1/2Gesunde Freiwillige willkommen
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Teilnehmer gesuchtPhase 2/3
- Seattle Cancer Care Alliance, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Teilnehmer gesuchtPhase 1/2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Teilnehmer gesuchtPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Teilnehmer gesuchtPhase 2
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Teilnehmer gesuchtPhase 1
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Teilnehmer gesuchtPhase 1
- Fred Hutchinson Cancer Center, Seattle
Myelodysplastische Syndrome-Studien in anderen Städten
- Houston, TX43 Studien
- Baldwin Park, CA26 Studien
- New York City, NY21 Studien
- Washington, DC20 Studien
- Boston, MA19 Studien
- Tampa, FL19 Studien
- Miami, FL17 Studien
- Columbus, OH14 Studien
- Durham, NC14 Studien
- Chicago, IL13 Studien
- Atlanta, GA13 Studien
- St. Louis, MO13 Studien
Weitere Studien in Seattle
- Nichtkleinzelliges Lungenkarzinom53 Studien
- Krebs (alle Arten)49 Studien
- Prostatakrebs42 Studien
- Akute myeloische Leukämie40 Studien
- Brustkrebs39 Studien
- Metastasierender Krebs39 Studien
- Kolorektales Karzinom34 Studien
- Lungenkrebs33 Studien
- Eierstockkrebs30 Studien
- Multiples Myelom22 Studien
- Akute lymphoblastische Leukämie21 Studien
- Blasenkrebs21 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.